TY - JOUR T1 - Assessment of MR Imaging and CT in Differentiating Hereditary and Nonhereditary Paragangliomas JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 1320 LP - 1326 DO - 10.3174/ajnr.A7166 VL - 42 IS - 7 AU - Y. Ota AU - S. Naganawa AU - R. Kurokawa AU - J.R. Bapuraj AU - A. Capizzano AU - J. Kim AU - T. Moritani AU - A. Srinivasan Y1 - 2021/07/01 UR - http://www.ajnr.org/content/42/7/1320.abstract N2 - BACKGROUND AND PURPOSE: Head and neck paragangliomas have been reported to be associated with mutations of the succinate dehydrogenase enzyme family. The aim of this study was to assess whether radiologic features could differentiate between paragangliomas in the head and neck positive and negative for the succinate dehydrogenase mutation.MATERIALS AND METHODS: This single-center retrospective review from January 2015 to January 2020 included 40 patients with 48 paragangliomas (30 tumors positive for succinate dehydrogenase mutation in 23 patients and 18 tumors negative for the succinate dehydrogenase mutation in 17 patients). ADC values and tumor characteristics on CT and MR imaging were evaluated by 2 radiologists. Differences between the 2 cohorts in the diagnostic performance of ADC and normalized ADC (ratio to ADC in the medulla oblongata) values were evaluated using the independent samples t test. P < .05 was considered significant.RESULTS: ADCmean (1.07 [SD, 0.25]/1.04 [SD, 0.12] versus 1.31 [SD, 0.16]/1.30 [SD, 0.20]× 10−3 mm2/s by radiologists 1 and 2; P < .001), ADCmaximum (1.49 [SD, 0.27]/1.49 [SD, 0.20] versus 2.01 [SD, 0.16]/1.87 [SD, 0.20] × 10−3 mm2/s; P < .001), normalized ADCmean (1.40 [SD, 0.33]/1.37 [SD, 0.16] versus 1.73 [SD, 0.22]/1.74 [SD, 0.27]; P < .001), and normalized ADCmaximum (1.95 [SD, 0.37]/1.97 [SD, 0.27] versus 2.64 [SD, 0.22]/2.48 [SD, 0.28]; P < .001) were significantly lower in succinate dehydrogenase mutation–positive than mutation–negative tumors. ADCminimum, normalized ADCminimum, and tumor characteristics were not statistically significant.CONCLUSIONS: ADC is a promising imaging biomarker that can help differentiate succinate dehydrogenase mutation–positive from mutation–negative paragangliomas in the head and neck.nADCnormalized ADCSDHsuccinate dehydrogenase ER -